Status Asthmaticus Clinical Trial
Official title:
A Prospective, Randomized, Controlled, Single Center Trial of the Use of Heliox in Children Admitted to the Hospital With Status Asthmaticus
The purpose of this study is to investigate whether heliox-powered albuterol nebulizer therapy will result in reduced inpatient length of stay in children hospitalized with acute asthma exacerbations.
We hypothesize that heliox-powered albuterol nebulizer therapy will result in reduced
inpatient length of stay in children hospitalized with acute asthma exacerbations. Severity
of asthma will be characterized using a modified Becker Clinical Asthma Score (CAS) based
upon the acuity of physical signs for four clinical characteristics (respiratory rate,
wheezing, I/E ratio, and accessory muscle use). Scoring will occur at the time of enrollment
and every 4 hours thereafter until the patient meets hospital discharge criteria. All
scoring using the CAS will be performed by an independent physician, nurse or respiratory
therapist blinded to the subject treatment arm. All children will receive standard
cardiopulmonary monitoring and treatment, consisting of supplemental oxygen delivered as
needed by either nasal cannula or face mask to maintain oxygen saturation >90%, maintenance
intravenous fluids, corticosteroid therapy and nebulized albuterol therapy. After written
informed consent, eligible children will be randomized to one of two study groups using a
sealed envelope technique:
Group 1 (Heliox-Powered Albuterol) patients will receive all albuterol nebulizer treatments,
including continuous therapy, powered by 70:30 Heliox.
Group 2 (Oxygen-Powered Albuterol) patients will receive all albuterol nebulizer treatments,
including continuous therapy, powered by 100% oxygen per usual standard of care.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02872597 -
Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus
|
Phase 1 | |
Terminated |
NCT02966184 -
Comparison of Albuterol for Status Asthmaticus
|
Phase 4 | |
Enrolling by invitation |
NCT00750568 -
Intravenous Terbutaline in Severe Status Asthmaticus
|
N/A | |
Completed |
NCT00124995 -
Trial of Terbutaline for the Treatment of Status Asthmaticus in Children
|
Phase 4 | |
Recruiting |
NCT05819541 -
Treating Exacerbations of Asthma With Oral Montelukast in Children
|
Phase 2 | |
Completed |
NCT01524198 -
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room
|
Phase 2/Phase 3 | |
Terminated |
NCT02780479 -
Steroids in Children Hospitalized With Asthma
|
Phase 4 | |
Withdrawn |
NCT01403428 -
Non Invasive Positive Pressure Ventilation in Status Asthmaticus
|
Phase 2 | |
Terminated |
NCT00683449 -
Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma
|
Phase 2 | |
Withdrawn |
NCT03219736 -
NiPPV in the Treatment of Acute Asthma Exacerbations
|
N/A | |
Completed |
NCT00722020 -
HFCWO in Hospitalized Asthmatic Children
|
N/A | |
Withdrawn |
NCT03338205 -
The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus
|
Phase 3 | |
Completed |
NCT02302261 -
Pleth Variability and Asthma Severity in Children
|
N/A | |
Recruiting |
NCT01770899 -
Evaluation Montelukast in the Treatment of Status Asthmaticus
|
N/A | |
Withdrawn |
NCT01188473 -
Early Noninvasive Positive Pressure Ventilation in Children With Status Asthmaticus
|
Phase 1 | |
Withdrawn |
NCT04656587 -
BPAP in Pediatric Asthma Pilot Study
|
N/A | |
Completed |
NCT04929626 -
Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus
|
Phase 1 | |
Completed |
NCT00623688 -
Effectiveness and Cost Study Comparing Two Ways to Deliver Albuterol for the Treatment of Asthma in the Hospital
|
N/A | |
Recruiting |
NCT00491790 -
Montelukast With Status Asthmaticus, Ages 2-5
|
Phase 2/Phase 3 | |
Recruiting |
NCT00494572 -
Montelukast With Status Asthmaticus, Ages 6-18
|
Phase 2/Phase 3 |